Recent News and Discussions About Adcomm Layoffs
Lundbeck slides after FDA rejects label claim … – Fierce Biotech
https://www.fiercebiotech.com/financials/lundbeck-slides-after-fda-rejects-label-claim-against-adcomm-recommendation
The layoffs will begin on July 1 and wrap up by April 1, 2023. Catalyst Biosciences: The company is at a corporate crossroads, emblematic in the decision to …
The Daily Biotech Pulse: FDA’s AdComm For Acadia’s …
https://markets.businessinsider.com/news/stocks/the-daily-biotech-pulse-fda-s-adcomm-for-acadia-s-pimavanserin-review-issues-for-spero-s-tebipenem-application-cortexyme-layoffs-1031414090
May 3, 2022 — The Daily Biotech Pulse: FDA’s AdComm For Acadia’s Pimavanserin, Review Issues For Spero’s Tebipenem Application, Cortexyme Layoffs .
Adcomm, Inc. Work-Life Balance reviews – Indeed
https://www.indeed.com/cmp/Adcomm,-Inc./reviews?fcountry=ALL&ftopic=wlbalance
They recently laid off 70% of the company. Not just random people, but entire departments. While they say that customer service is “safe” … no one feels that …
Working at Adcomm, Inc.: 56 Reviews about Pay & Benefits
https://www.indeed.com/cmp/Adcomm,-Inc./reviews?ftopic=paybenefits
Layoffs are drastic with no notice. Compensation is poor with very few/too expensive benefits. Lower level managers are usually great though.
FDA’s AdComm For Acadia’s Pimavanserin, Review Issues …
https://www.benzinga.com/general/biotech/22/05/26958446/the-daily-biotech-pulse-fdas-adcomm-for-acadias-pimavanserin-review-issues-for-speros-tebipenem-a
May 3, 2022 — The Daily Biotech Pulse: FDA’s AdComm For Acadia’s Pimavanserin, Review Issues For Spero’s Tebipenem Application, Cortexyme Layoffs · Stocks In …
Adcomm – Good starter job | Glassdoor
https://www.glassdoor.com/Reviews/Employee-Review-Adcomm-RVW39856869.htm
Poor management with no regards to layoffs during slow seasons. Continue reading. Be the first to find this review helpful. Helpful.
Oncopeptides stock craters as it pulls cancer drug Pepaxto …
Oncopeptides stock craters as it pulls cancer drug Pepaxto from the market
The move will force the company to close its US and EU business units and enact significant layoffs . The FDA had scheduled an adcomm meeting next Thursday …
bluebird bio Soars as FDA Adcom Recommends Second …
https://www.biospace.com/article/bluebird-bio-still-in-flight-as-fda-adcom-recommends-second-gene-therapy-/
Jun 10, 2022 — bluebird bio Soars as FDA Adcom Recommends Second Gene Therapy … in much revenue and it has made rounds of layoffs to keep the doors open.
Cortexyme Announces Further Layoffs, Chief Medical Officer …
https://www.yahoo.com/lifestyle/cortexyme-announces-further-layoffs-chief-135639997.html
May 3, 2022 — Price Action: Monday, CRTX shares traded 0.72% lower at $47.99. See more from Benzinga. The Daily Biotech Pulse: FDA’s AdComm For Acadia’s …
FiercePharmaAsia—Astellas job cuts, GSK vet’s $260M …
https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-astellas-reorg-gsk-vet-s-260m-chinese-startup-sun-pharma-s-zytiga
Astellas’ new CEO is pushing for a round of layoffs in R&D and sales and marketing that … Innovent China trial for lung cancer drug Tyvyt, says FDA AdComm .